The Predictive Biomarkers of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Predictive Biomarkers of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

Published:2024 Issue:05 Volume:14 Page:2302-2310
ISSN:2161-8712
Container-title:Advances in Clinical Medicine
language:
Short-container-title:ACM

Author:

贾轩超

Publisher

Hans Publishers

Reference46 articles.

1. Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

2. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

3. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

4. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

5. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3